Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
PDF) Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
News on Diffuse Large B-Cell Lymphoma » Coping with Cancer
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B -cell Lymphoma - ScienceDirect
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication | Cell Death & Disease
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
Diffuse Large B-Cell Lymphoma | NEJM
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma | Acta Pharmacologica Sinica
Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
